![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Lilly’s Plaque Psoriasis Treatment Nabs FDA Approval
Lilly’s Plaque Psoriasis Treatment Nabs FDA Approval
March 28, 2016
The FDA has approved Eli Lilly’s Taltz to treat moderate to severe plaque psoriasis.
The approval was based on clinical trials that evaluated the injectable treatment in 3,866 participants with plaque psoriasis who were eligible for systemic therapy.
The drug is approved with a medicine guide, as it poses risks to the immune system. Side effects include upper respiratory infections, injection site reactions and tinea infections.
Upcoming Events
-
21Oct